Source: Eur Respir J 2012; 39: 797-798
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Luisetti M., Stolk J., Iadarola P.. Desmosine, a biomarker for COPD: old and in the way. Eur Respir J 2012; 39: 797-798

Member's Comments

No comment yet.

Related content which might interest you: Towards the next stage of novel biomarker discussion in COPD: Tekizai-Tekisho Source: Eur Respir J 2014; 43: 322-324 Year: 2013 What is the best biomarker of COPD stability? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Pro-surfactant protein B, a promising BAL biomarker of COPD progression in heavy smokers, is increased by budesonide/formoterol short-term therapy Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers Source: International Congress 2014 – Markers Year: 2014 Microarray profiling of COPD patients versus non-COPD smokers reveals possible disease biomarkers Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Microalbuminuria as a cardiovascular biomarker in patients with COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker? Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Endothelial microparticles in sputum of COPD patients: A potential biomarker of disease Source: International Congress 2015 – Systemic and airway biomarkers Year: 2015 Accelerated aging biomarkers in young, old, mild and severe COPD Source: Virtual Congress 2021 – Pathogenic progress in airway diseases Year: 2021 Can YKL-40 be used as a biomarker and therapeutic target for adult asthma? Source: Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017 Year: 2018 The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm Source: Eur Respir J, 59 (2) 2102669; 10.1183/13993003.02669-2021 Year: 2022 COPD in women: a particular phenotype Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019 COPD in nonsmokers: the biomass hypothesis – to be or not to be? Source: Eur Respir J 2014; 44: 8-10 Year: 2014 L-arginine pathway metabolites can predict exacerbation independently from beta blocker treatment in patients with COPD: A follow-up study Source: International Congress 2016 – Systemic biomarkers Year: 2016 Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD Source: Eur Respir J 2014; 43: 951-953 Year: 2014 Methylated arginine derivatives can differ stable and unstable patients with COPD Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 Increased urinary LTE4 in severe asthma and COPD: interim report from the BIOAIR study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 COPD specific comorbidities: A prospective, objective and controlled evaluation Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 A follow-up study (MARKO) supports the need to change the diagnostic criteria for COPD Source: International Congress 2016 – New approaches and finding in smoking cessation Year: 2016 Spirometry screening in the community: is this an effective way of diagnosing early COPD? Source: Annual Congress 2005 - Assessment and intervention from primary care centre to hospital Year: 2005